drugset

drugset / Trial / NCT02970019

Safety and Tolerability Study of K0706 in Subjects With Parkinson's Disease

NCT02970019 ↗

Phase 1 Completed 60 enrolled Sun Pharma Advanced Research Company Limited

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a safety, tolerability and pharmacokinetic study in subjects with Parkinson's disease

Timeline

Start: 2017-03-30
Primary completion: 2019-05-28
Completion: 2019-05-28

Publications

Joshi D, Kulkarni M, Parekh P, Shah S, Greig NH, Acharya S. Targeting protein kinases in Parkinson's disease: the emerging role of phytoconstituents. Nutr Neurosci. 2025 Dec;28(12):1532-1563. doi: 10.1080/1028415X.2025.2531356. Epub 2025 Jul 18.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Vodobatinib	Small molecule	—	—

Indications